# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Confirming the functional benefits, the FDA granted traditional approval for ambulatory patients. The FDA granted accelerated...
BMO Capital analyst Kostas Biliouris maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $170 price...
BMO Capital analyst Kostas Biliouris maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $170 price...
Piper Sandler analyst Biren Amin initiates coverage on Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight rating and annou...